NCT00003222View on ClinicalTrials.gov

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 1998

Primary Completion Date

September 30, 2003

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

aldesleukin

Systemic subcutaneous delivery of low-dose IL-2.

BIOLOGICAL

gp100 antigen

BIOLOGICAL

incomplete Freund's adjuvant

BIOLOGICAL

sargramostim

BIOLOGICAL

tetanus peptide melanoma vaccine

BIOLOGICAL

tyrosinase peptide

Trial Locations (1)

22908

Cancer Center at the University of Virginia, Charlottesville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Virginia

OTHER

NCT00003222 - Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | Biotech Hunter | Biotech Hunter